ERBB2 and neoplasm: Furthermore, Her2 status shows heterogeneity between tumor, lymph node, and organ metastasis and up to 30% of patients are reported to switch Her2 receptor status following a neoadjuvant therapy with anti-Her2 directed antibody trastuzumab [17].